Medical Condition News

RSS

U.S. FDA orders three TMJ implant manufacturers to conduct postmarket surveillance studies

Today the U.S. Food and Drug Administration ordered three manufacturers of temporomandibular joint implants to conduct postmarket surveillance studies to determine the length of time before the implants are removed or replaced due to pain or other reasons.

8 Feb 2011

Cleveland Clinic, JumpStart Ventures invest $500,000 in SironRX Therapeutics

JumpStart Ventures, the non-profit that invests in and partners with innovative, early-stage companies in Northeast Ohio, and Cleveland Clinic, announced a combined investment commitment of $500,000 in SironRX Therapeutics, Inc. The Cleveland-based company is developing a topical therapy to enhance healing of and decrease scar formation in wounds.

8 Feb 2011

Schizophrenia patients who consume antipsychotics appear to lose small amount of brain tissue

Patients with schizophrenia who take antipsychotic medications appear to lose a small but measurable amount of brain tissue over time, according to a report in the February issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Feb 2011

Study reports significant decline in second-generation medication use for dementia

As loved ones with dementia disappear into symptoms of aggression, agitation or delusions, families are left with few good medical solutions. A new generation of antipsychotic medications gained popularly in the 1990s because they avoided side effects such as Parkinson's syndrome associated with conventional antipsychotic medications used to treat dementia.

8 Feb 2011

Munich research team provides promising alternative to DNA-based procedures

Defects in the genome are the cause of many diseases. Gene therapy - direct replacement of mutant genes by intact DNA copies - offers a means of correcting such defects. Now a research team based at the Medical Center of the University of Munich, and led by Privatdozent Dr. Carsten Rudolph, has taken a new approach that avoids DNA delivery.

8 Feb 2011

Researchers identify enzyme that protects against inflammation, joint destruction

A team of researchers at the University of Gothenburg, Sweden, has identified an enzyme that protects against inflammation and joint destruction. Made when the researchers blocked production of the enzyme GGTase-I in transgenic mice, this unexpected discovery could lead to the identification of new mechanisms that control the development of inflammatory disorders, as well as new medicines.

8 Feb 2011

Immune system genes linked to personality traits, mental illness and suicidal behaviour

Genes linked to the immune system can affect healthy people's personality traits as well as the risk of developing mental illness and suicidal behaviour, reveals a thesis from the University of Gothenburg, Sweden.

8 Feb 2011

Study: Cannabis use appears to be linked with earlier onset of psychotic illness

Cannabis use appears to be associated with an earlier onset of psychotic illness, according to a meta-analysis of previously published studies posted online today that will appear in the June print issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

8 Feb 2011

Study reveals Facebook users may face risk of developing eating disorders

The same has been found with regard to exposure to music and fashion on the Internet, and to harmful programs on TV. The study also reveals that the risk of developing eating disorders in adolescent girls is moderated when there is more parental supervision over viewing habits.

8 Feb 2011

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

After analyzing hundreds of proteins produced by the DNA of tumor cells, researchers have identified one protein that may be central to a new treatment for the often-fatal childhood cancer neuroblastoma. Oncologists hope to translate the finding into pediatric clinical trials of a drug that blocks the protein's activity.

7 Feb 2011

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

PharmaMar SA has announced the commencement of a Phase I clinical trial with PM060184 for patients with solid tumors. PM060184 is a marine-derived, synthetically-produced compound which has shown strong in vitro and in vivo antitumor activity and a favorable safety profile in preclinical toxicology studies. PM060184 is PharmaMar's sixth compound in clinical development.

7 Feb 2011

USPTO issues key patent to ISTO's NuQu product for degenerative disc disease treatment

ISTO Technologies, Inc. announced today that the United States Patent and Trademark Office has granted the company a key patent covering the primary technology for ISTO's NuQu product.

7 Feb 2011

NIMH awards two BUSM members with BRAINS grant for innovative research on mental disorders

Two Boston University School of Medicine faculty members, Pietro Cottone, PhD, an assistant professor of pharmacology and psychiatry and Michael Silverstein, MD, an associate professor of pediatrics, were each awarded the prestigious National Institute of Mental Health Biobehavioral Research Awards for Innovative New Scientisits grant with ten other investigators from around the country.

7 Feb 2011

CMD co-founder receives Prize4Life award for discovery of new ALS biomarker

Convergence Medical Devices (CMD) today announced that its co-founder, Dr. Seward Rutkove, Chief of the Division of Neuromuscular Disease at Beth Israel Deaconess Medical Center and Associate Professor of Neurology at Harvard Medical School, received Prize4Life's prestigious award for the discovery of a new biomarker for ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig's disease.

7 Feb 2011

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

A low cost, nanometer-sized drug to treat chronic wounds, such as diabetic foot ulcers or burns, has been developed by a group of scientists from the Hebrew University of Jerusalem, Harvard Medical School and others in the U.S. and Japan.

7 Feb 2011

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.

7 Feb 2011

Psychiatric symptoms of bed breath

A study, published in the last 2010 issue of Psychotherapy and Psychosomatics by a group of researchers of the University of Torino (Italy), has explored the personality correlates and psychiatric symptoms of bed breath.

7 Feb 2011

Reliv International launches new nutritional supplement to address entire fatigue cycle

Consumers who are fighting the fatigue cycle -- physical fatigue, mental fog and stress -- now have a new means of breaking that cycle. Reliv 24K, a new nutritional supplement, is the first shot to provide healthy energy and greater mental focus while also reducing stress. Reliv International, Inc., a creator of nutritional supplements that promote optimal health, introduced the product last weekend in Atlanta.

7 Feb 2011

Toshiba's Aquilion ONE dynamic volume CT system to improve stroke diagnosis, treatment

Containing costs while delivering high-quality, effective care is a directive of healthcare reform. Episode-based care is part of the reform mandate and is a payment approach that reimburses on expected costs for clinically defined episodes rather than fee-for-service.

7 Feb 2011

The Lancet journal publishes BENLYSTA BLISS-52 study against SLE

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced publication of the BLISS-52 study of BENLYSTA in autoantibody-positive patients with active systemic lupus erythematosus in The Lancet.

7 Feb 2011

Medical Condition News

U.S. FDA orders three TMJ implant manufacturers to conduct postmarket surveillance studies

Cleveland Clinic, JumpStart Ventures invest $500,000 in SironRX Therapeutics

Schizophrenia patients who consume antipsychotics appear to lose small amount of brain tissue

Study reports significant decline in second-generation medication use for dementia

Munich research team provides promising alternative to DNA-based procedures

Researchers identify enzyme that protects against inflammation, joint destruction

Immune system genes linked to personality traits, mental illness and suicidal behaviour

Study: Cannabis use appears to be linked with earlier onset of psychotic illness

Study reveals Facebook users may face risk of developing eating disorders

Researchers identify CHK1 protein may serve as treatment target for neuroblastoma

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

USPTO issues key patent to ISTO's NuQu product for degenerative disc disease treatment

NIMH awards two BUSM members with BRAINS grant for innovative research on mental disorders

CMD co-founder receives Prize4Life award for discovery of new ALS biomarker

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

Psychiatric symptoms of bed breath

Reliv International launches new nutritional supplement to address entire fatigue cycle

Toshiba's Aquilion ONE dynamic volume CT system to improve stroke diagnosis, treatment

The Lancet journal publishes BENLYSTA BLISS-52 study against SLE

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Latest News